Vortex “As a clinician, I am excited about accessing the cancer biology of patient’s through CTCs. Vortex’s technology provides the best source of CTCs to aid in the diagnostic and treatment decisions we face every day.” – Dr. Jonathan Goldman, MD, Director of Clinical Trials in Thoracic Oncology, Associate Director of Drug Development at UCLA “Improving CTCs recovery along with high cellular purity while maintaining viability have tremendous value for translational research and clinical diagnostic applications. The VTX-1 holds the potential to revolutionize blood-based diagnostics.” - Pr. Massimo Cristofanilli, MD, FACP, Professor of Medicine, Associate Director of Translational Research and Precision Medicine, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine Wanda J. Cribbs, Lead Gartner Analyst Population Health & Analytics says: "Wanda's recent HRS press release really stands out. Delivering those results and having a client publicly share credit with their vendor is rare and says a lot. We at Gartner will have our eyes on Wanda in 2018"

Media

All the posts published.

NetScientific gaining critical mass with commercial ramp-up of portfolio

Dec 14, 2017
-
Media, News, Wanda Health

Francois Martelet, chief executive of NetScientific PLC (LON:NSCI) caught up with Proactive’s Andrew Scott to update on developments within the IP commercialisation specialist’s portfolio. Francois Martelet, chief executive of NetScientific PLC (LON:NSCI), caught up with Proactive’s Andrew Scott to update on developments within the IP commercialisation specialist’s portfolio. ”All of our companies are game-changing and unique in their sectors”, Martelet says. Most recently NetScientific …

NetScientific H1 2018 Planned Investor Event and Conference Attendance

Jan 6, 2018
-
Media, News

London, UK – 05 January 2018 – NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation group, today announces that its management team will attend the following key investor and partnering conferences in the first half of 2018: IDATE DigiWorld – London Members Yearly Meeting January 18th 2018 London, UK Francois Martelet, CEO, to attend   BAB TAG Networking Event January 24th 2018 London, UK …

NetScientific CEO to Present at Shares Investor Evening at 19:30 on the 14th December 2017

Dec 8, 2017
-
Media, News

  London, UK – 08 December 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group announces that Francois Martelet, Chief Executive Officer, will be presenting at the Shares Investor Evening in London at the Novotel Tower Bridge, London EC3N 2NR on Thursday 14 December at 19:30 GMT # # # For more information, please contact: NetScientific François R. Martelet, M.D., …

EXECUTIVE INTERVIEW – NETSCIENTIFIC

Oct 11, 2017
-
Media, News

 

NetScientific chief François Martelet on the ‘strong return’ from sale of OncoVerse

Apr 25, 2017
-
Media, News

Netscientific Overview 2017 Video

Apr 25, 2017
-
Media, News

François Martelet M.D Netscientific Chief Executive Officer speaks about Netscientific transatlantic healthcare technology group. NetScientific is a transatlantic healthcare IP commercialisation group. We fund and develop companies that significantly improve the health and well-being of people with chronic diseases. Through our US-UK network, we source, develop and manage early/mid-stage healthcare technology companies focused on Diagnostics, Digital health and Therapeutics. We are focused on …

SLAS 2017 Innovation Award for VortexBioSciences Liquid Biopsy Video

Mar 16, 2017
-
Media, News, Vortex BioSciences

NetScientific – François Martelet M.D. Chief Executive Officer proud of cancer diagnostic tool’s achievements

Feb 23, 2017
-
Media, News, Vortex BioSciences

NetScientific plc chief hails progress at Vortex Biosciences

Nov 7, 2016
-
Media, News, Vortex BioSciences

NetScientific plc (LON:NSCI) chief executive and chairman Francois Martelet hailed recent news from portfolio company Vortex Biosciences as a “very important” milestone. Vortex has been awarded a CE Mark for its circulating tumour cell (CTC) capture system and has registered a Class I medical device with the US FDA (Food and Drug Administration). It means moving the selling of the VTX-1 Liquid Biopsy …

NetScientific PLC focused on “execution, execution and execution”

Sep 27, 2016
-
Glycotest, Media, News, ProAxsis, Vortex BioSciences, Wanda Health

Biomedical and healthcare incubator NetScientific PLC (LON:NSCI) had a busy first half to the year, focusing on “execution, execution, execution”, according to chief executive officer François Martelet. Backed by its world class scientific advisory boards, the investment company’s emphasis has been on accelerating its core portfolio companies – Wanda, Vortex Biosciences, Glycotest and ProAxsis – towards the commercialisation stage. That will set them …

Media Archives - NetScientific